Role of CD47-SIRPα Checkpoint in Nanomedicine-Based Anti-Cancer Treatment

Haiqin Liao; Haiqin Liao; Chengcheng Niu; Chengcheng Niu

doi:10.3389/fbioe.2022.887463

Frontiers in Bioengineering and Biotechnology (Apr 2022)

Role of CD47-SIRPα Checkpoint in Nanomedicine-Based Anti-Cancer Treatment

Haiqin Liao,
Haiqin Liao,
Chengcheng Niu,
Chengcheng Niu

Affiliations

Haiqin Liao: Department of Ultrasound Diagnosis, The Second Xiangya Hospital, Central South University, Changsha, China
Haiqin Liao: Research Center of Ultrasonography, The Second Xiangya Hospital, Central South University, Changsha, China
Chengcheng Niu: Department of Ultrasound Diagnosis, The Second Xiangya Hospital, Central South University, Changsha, China
Chengcheng Niu: Research Center of Ultrasonography, The Second Xiangya Hospital, Central South University, Changsha, China

DOI: https://doi.org/10.3389/fbioe.2022.887463
Journal volume & issue: Vol. 10

Abstract

Read online

Many cancers have evolved various mechanisms to evade immunological surveillance, such as the inhibitory immune checkpoint of the CD47-SIRPα signaling pathway. By targeting this signaling pathway, researchers have developed diverse nanovehicles with different loaded drugs and modifications in anticancer treatment. In this review, we present a brief overview of CD47-SIRPα interaction and nanomedicine. Then, we delve into recent applications of the CD47-SIRPα interaction as a target for nanomedicine-based antitumor treatment and its combination with other targeting pathway drugs and/or therapeutic approaches.

Published in Frontiers in Bioengineering and Biotechnology

ISSN: 2296-4185 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Technology: Chemical technology: Biotechnology
Website: http://www.frontiersin.org/bioengineering_and_biotechnology

About the journal

Abstract

Keywords